Gibson Dunn Advising Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent $200 Million Financings
Firm News | December 17, 2025
Gibson Dunn is advising Yarrow Bioscience on its merger with VYNE Therapeutics and concurrent $200 million financings.
Our corporate team includes partners Ryan Murr, Melanie Neary, and Branden Berns and associates Evan Shepherd and Candice Johnson.